{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"191-951-650-240-47X","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"191-951-650-240-47X","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10806,"type":"PATENT","title":" Technion-Israel Institute of Technology - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1908,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8271,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \" Technion Israel Inst Techno\"; \"Techni* Israel Inst* Techno*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4
Search Applicants and Owners separately: \" Technion Israel Inst Techno\"; \"Techni* Israel Inst* Techno*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4
wherein the set of VOCs indicative of breast cancer comprises at least one of 2-amino-5-isopropyl-8-methyl-1-azulenecarbonitrile, 6-ethyl-3-octyl ester-2-trifluoromethylbenzoic acid, 2,3,4,6-tetramethoxystyrene, 2,4,6-tris(1-methylethyl)-phenol, 1,3,5-cycloheptatriene, and 2-methoxy-acetate ethanol; or\n
wherein the set of VOCs indicative of colon cancer comprises 1,3,5-cycloheptatriene; or\n
wherein the set of VOCs indicative of head and neck cancer comprises at least one of butylated hydroxytoluene, 1-methyl-3-(1-methylethyl)-benzene, and 4,6-di(1,1-dimethylethyl)-2-methyl-phenol; or\n
wherein the set of VOCs indicative of prostate cancer comprises at least one of 2-amino-5-isopropyl-8-methyl-1-azulenecarbonitrile, 2,2-dimethyl-decane, carbonic dihydrazide, 4,6-di(1,1-dimethylethyl)-2-methyl-phenol, and butylated hydroxytoluene."],"number":45,"annotation":false,"claim":true,"title":false},{"lines":["The set according to claim 45, wherein the set of VOCs indicative of breast cancer further comprises 2-methyl-1,3-butadiene; or wherein the set of VOCs indicative of breast cancer further comprises at least one additional volatile organic compound selected from the group consisting of 3,3-dimethyl-pentane, 5-(2-methylpropyl)-nonane, 2,3,4-trimethyl-decane, 2,2,4,4,6,8,8-heptamethyl-nonane, ethyl benzene, 2,2,4,4,5,5,7,7-octamethyloctane, hydroxymethyl 2-hydroxy-2-methylpropionate, and 2-methyl-hexane."],"number":46,"annotation":false,"claim":true,"title":false},{"lines":["The set according to claim 45, wherein the set of VOCs indicative of colon cancer further comprises at least one of 2-methyl-1,3-butadiene and dimethyl-diazene; or wherein the set of VOCs indicative of colon cancer further comprises at least one additional volatile organic compound selected from the group consisting of 1,3-dimethyl benzene, 4-(4-propylcyclohexyl)-4′-cyano[1,1′-biphenyl]-4-yl ester benzoic acid, 1-methyl-3-(1-methylethyl)-benzene, 1,1′-(1-butenylidene)bis-benzene, 1-iodo-nonane, [(1,1-dimethylethyl)thio]-acetic acid, 2-amino-5-isopropyl-8-methyl-1-azulenecarbonitrile, 3,3-dimethyl-hexane, 1-ethyl-2,4-dimethyl-benzene, 2,4,6-tris(1-methylethyl)-phenol, 1,1′-(3-methyl-1-propene-1,3-diyl)bis-benzene, 2,6-bis(1,1-dimethylethyl)-4-methyl-methylcarbamate phenol, trans-1,4-diethylcyclohexane, ammonium acetate, and 2,2,3-trimethyl-endo-bicyclo[2.2.1]heptane."],"number":47,"annotation":false,"claim":true,"title":false},{"lines":["The set according to claim 45, wherein the set of VOCs indicative of head and neck cancer further comprises at least one additional volatile organic compound selected from the group consisting of 2-methyl-1,3-butadiene and 1,3-pentadiene; or wherein the set of VOCs indicative of head and neck cancer further comprises at least one additional volatile organic compound selected from the group consisting of 2-acetylmethylamino-4,5,6,7-tetrahydrobenzothiazol-7-one, 2,2,4,4,6,8,8-heptamethyl-nonane, 4-(4-propylcyclohexyl)-4′-cyano[1,1′-biphenyl]-4-yl ester benzoic acid, carbonic dihydrazide, 2,2,3-trimethyl-bicyclo[2.2.1]heptane, and 1-propanol."],"number":48,"annotation":false,"claim":true,"title":false},{"lines":["The set according to claim 45, wherein the set of VOCs indicative of prostate cancer further comprises at least one additional volatile organic compound selected from the group consisting of 2-methyl-1,3-butadiene and p-xylene; or wherein the set of VOCs indicative of prostate cancer further comprises at least one additional volatile organic compound selected from the group consisting of toluene, 2,2,4,4,5,5,7,7-octamethyloctane, 1,1′-(1,3,3-trimethyl-1-propene-1,3-diyl)bis-benzene, ∘-phellandrene, dimethyl-diazene, and 1-ethyl-3,5-dimethyl-benzene."],"number":49,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosing, monitoring or prognosing breast cancer in a subject comprising the steps of:\n
a) collecting a test breath sample from a test subject;\n
b) determining the level of at least one volatile organic compound from a set of VOCs indicative of breast cancer according to claim 45 in the test sample; and\n
c) comparing the level of the at least one volatile organic compound from the test sample with the level of said at least one volatile organic compound in a control sample, whereby a significantly different level of said at least one volatile organic compound in the test sample as compared to the level of said compound in the control sample is indicative of breast cancer."],"number":50,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 50, wherein the level of the at least one volatile organic compound is increased in the test sample as compared with the level of said compound in the control sample; or wherein the level of the at least one volatile organic compound is decreased in the test sample as compared with the level of said compound in the control sample."],"number":51,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 50, wherein the test subject is a mammal; or wherein the test subject is selected from a subject who is at risk of developing breast cancer, a subject who is suspected of having breast cancer, and a subject who is afflicted with breast cancer."],"number":52,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 50, comprising the step of determining the levels of a plurality of VOCs indicative of breast cancer in the test sample, wherein the levels of the plurality of VOCs form a pattern which is significantly different from the pattern of said VOCs in the control sample."],"number":53,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 53, wherein the pattern is analyzed with a pattern recognition analyzer, wherein the pattern recognition analyzer comprises at least one algorithm selected from the group consisting of principal component analysis (PCA), artificial neural network algorithms, multi-layer perception (MLP), generalized regression neural network (GRNN), fuzzy inference systems (FIS), self-organizing map (SOM), radial bias function (RBF), genetic algorithms (GAS), neuro-fuzzy systems (NFS), adaptive resonance theory (ART), partial least squares (PLS), multiple linear regression (MLR), principal component regression (PCR), discriminant function analysis (DFA), linear discriminant analysis (LDA), cluster analysis, and nearest neighbor."],"number":54,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 53, wherein the step of determining the levels of a plurality of VOCs comprises the use of at least one technique selected from the group consisting of Gas-Chromatography (GC), GC-lined Mass-Spectrometry (GC-MS), Proton Transfer Reaction Mass-Spectrometry (PTR-MS), Electronic nose device, and Quartz Crystal Microbalance (QCM); or wherein the step of determining the levels of a plurality of VOCs comprises the use of Gas-Chromatography-Mass Spectrometry (GC-MS) combined with solid phase microextraction (SPME)."],"number":55,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosing, monitoring or prognosing colon cancer in a subject comprising the steps of:\n
a) collecting a test breath sample from a test subject;\n
b) determining the level of at least one volatile organic compound from a set of VOCs indicative of colon cancer according to claim 45 in the test sample; and\n
c) comparing the level of the at least one volatile organic compound from the test sample with the level of said at least one volatile organic compound in a control sample, whereby a significantly different level of said at least one volatile organic compound in the test sample as compared to the level of said compound in the control sample is indicative of colon cancer."],"number":56,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 56, wherein the level of the at least one volatile organic compound is increased in the test sample as compared with the level of said compound in the control sample; or wherein the level of the at least one volatile organic compound is decreased in the test sample as compared with the level of said compound in the control sample."],"number":57,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 56, wherein the test subject is a mammal; or wherein the test subject is selected from a subject who is at risk of developing colon cancer, a subject who is suspected of having colon cancer, and a subject who is afflicted with colon cancer."],"number":58,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 56, comprising the step of determining the levels of a plurality of VOCs indicative of colon cancer in the test sample, wherein the levels of the plurality of VOCs form a pattern which is significantly different from the pattern of said VOCs in the control sample."],"number":59,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 59, wherein the pattern is analyzed with a pattern recognition analyzer, wherein the pattern recognition analyzer comprises at least one algorithm selected from the group consisting of principal component analysis (PCA), artificial neural network algorithms, multi-layer perception (MLP), generalized regression neural network (GRNN), fuzzy inference systems (FIS), self-organizing map (SOM), radial bias function (RBF), genetic algorithms (GAS), neuro-fuzzy systems (NFS), adaptive resonance theory (ART), partial least squares (PLS), multiple linear regression (MLR), principal component regression (PCR), discriminant function analysis (DFA), linear discriminant analysis (LDA), cluster analysis, and nearest neighbor."],"number":60,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 59, wherein the step of determining the levels of a plurality of VOCs comprises the use of at least one technique selected from the group consisting of Gas-Chromatography (GC), GC-lined Mass-Spectrometry (GC-MS), Proton Transfer Reaction Mass-Spectrometry (PTR-MS), Electronic nose device, and Quartz Crystal Microbalance (QCM); or wherein the step of determining the levels of a plurality of VOCs comprises the use of Gas-Chromatography-Mass Spectrometry (GC-MS) combined with solid phase microextraction (SPME)."],"number":61,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosing, monitoring or prognosing head and neck cancer in a subject comprising the steps of:\n
a) collecting a test breath sample from a test subject;\n
b) determining the level of at least one volatile organic compound from a set of VOCs indicative of head and neck cancer according to claim 45 in the test sample; and\n
c) comparing the level of the at least one volatile organic compound from the test sample with the level of said at least one volatile organic compound in a control sample, whereby a significantly different level of said at least one volatile organic compound in the test sample as compared to the level of said compound in the control sample is indicative of head and neck cancer."],"number":62,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 62, wherein the level of the at least one volatile organic compound is increased in the test sample as compared with the level of said compound in the control sample; or wherein the level of the at least one volatile organic compound is decreased in the test sample as compared with the level of said compound in the control sample."],"number":63,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 62, wherein the test subject is a mammal; or wherein the test subject is selected from a subject who is at risk of developing head and neck cancer, a subject who is suspected of having head and neck cancer, and a subject who is afflicted with head and neck cancer."],"number":64,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 62, comprising the step of determining the levels of a plurality of VOCs indicative of head and neck cancer in the test sample, wherein the levels of the plurality of VOCs form a pattern which is significantly different from the pattern of said VOCs in the control sample."],"number":65,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 65, wherein the pattern is analyzed with a pattern recognition analyzer, wherein the pattern recognition analyzer comprises at least one algorithm selected from the group consisting of principal component analysis (PCA), artificial neural network algorithms, multi-layer perception (MLP), generalized regression neural network (GRNN), fuzzy inference systems (FIS), self-organizing map (SOM), radial bias function (RBF), genetic algorithms (GAS), neuro-fuzzy systems (NFS), adaptive resonance theory (ART), partial least squares (PLS), multiple linear regression (MLR), principal component regression (PCR), discriminant function analysis (DFA), linear discriminant analysis (LDA), cluster analysis, and nearest neighbor."],"number":66,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 65, wherein the step of determining the levels of a plurality of VOCs comprises the use of at least one technique selected from the group consisting of Gas-Chromatography (GC), GC-lined Mass-Spectrometry (GC-MS), Proton Transfer Reaction Mass-Spectrometry (PTR-MS), Electronic nose device, and Quartz Crystal Microbalance (QCM); or wherein the step of determining the levels of a plurality of VOCs comprises the use of Gas-Chromatography-Mass Spectrometry (GC-MS) combined with solid phase microextraction (SPME)."],"number":67,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosing, monitoring or prognosing prostate cancer in a subject comprising the steps of:\n
a) collecting a test breath sample from a test subject;\n
b) determining the level of at least one volatile organic compound from a set of VOCs indicative of prostate cancer according to claim 45 in the test sample; and\n
c) comparing the level of the at least one volatile organic compound from the test sample with the level of said at least one volatile organic compound in a control sample, whereby a significantly different level of said at least one volatile organic compound in the test sample as compared to the level of said compound in the control sample is indicative of prostate cancer."],"number":68,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 68, wherein the level of the at least one volatile organic compound is increased in the test sample as compared with the level of said compound in the control sample; or wherein the level of the at least one volatile organic compound is decreased in the test sample as compared with the level of said compound in the control sample."],"number":69,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 68, wherein the test subject is a mammal; or wherein the test subject is selected from a subject who is at risk of developing prostate cancer, a subject who is suspected of having prostate cancer, and a subject who is afflicted with prostate cancer."],"number":70,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 68, comprising the step of determining the levels of a plurality of VOCs indicative of prostate cancer in the test sample, wherein the levels of the plurality of VOCs form a pattern which is significantly different from the pattern of said VOCs in the control sample."],"number":71,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 71, wherein the pattern is analyzed with a pattern recognition analyzer, wherein the pattern recognition analyzer comprises at least one algorithm selected from the group consisting of principal component analysis (PCA), artificial neural network algorithms, multi-layer perception (MLP), generalized regression neural network (GRNN), fuzzy inference systems (FIS), self-organizing map (SOM), radial bias function (RBF), genetic algorithms (GAS), neuro-fuzzy systems (NFS), adaptive resonance theory (ART), partial least squares (PLS), multiple linear regression (MLR), principal component regression (PCR), discriminant function analysis (DFA), linear discriminant analysis (LDA), cluster analysis, and nearest neighbor."],"number":72,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 71, wherein the step of determining the levels of a plurality of VOCs comprises the use of at least one technique selected from the group consisting of Gas-Chromatography (GC), GC-lined Mass-Spectrometry (GC-MS), Proton Transfer Reaction Mass-Spectrometry (PTR-MS), Electronic nose device, and Quartz Crystal Microbalance (QCM); or wherein the step of determining the levels of a plurality of VOCs comprises the use of Gas-Chromatography-Mass Spectrometry (GC-MS) combined with solid phase microextraction (SPME)."],"number":73,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}